abstract |
The present invention relates to dosing regimens of anti-TIGIT antibodies useful in the treatment of cancer. In particular, the present invention relates to such dosing regimens in combination therapy comprising administering antibodies to programmed death 1 protein (PD-1) or programmed death ligand 1 (PD-L1) and anti-TIGIT Antibody. |